Adamis Pharmaceuticals Corporation (ADMP) Receives Daily Media Sentiment Rating of 0.14
News headlines about Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) have trended somewhat positive this week, according to Accern. The research firm identifies negative and positive media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Adamis Pharmaceuticals Corporation earned a news impact score of 0.14 on Accern’s scale. Accern also assigned media headlines about the specialty pharmaceutical company an impact score of 46.555200544281 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the media headlines that may have effected Accern’s scoring:
- B. Riley Analysts Give Adamis Pharmaceuticals Corporation (ADMP) a $10.00 Price Target (americanbankingnews.com)
- Adamis Pharmaceuticals Could Explode Over 130 Percent (guerillastocktrading.com)
- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) – Where Relative Volume Stands? – Alpha Beta Stock (alphabetastock.com)
- Adamis Pharmaceuticals Corporation (ADMP) Revamps Its Position for Performance Measures – Stock News Stop (stockmarketstop.com)
- Adamis Pharmaceuticals Corporation Expected to Earn FY2017 Earnings of ($0.78) Per Share (ADMP) (americanbankingnews.com)
A number of research analysts have recently issued reports on the company. Raymond James Financial, Inc. assumed coverage on Adamis Pharmaceuticals Corporation in a report on Tuesday, September 12th. They issued an “outperform” rating and a $7.00 target price on the stock. B. Riley reissued a “buy” rating and issued a $9.50 target price on shares of Adamis Pharmaceuticals Corporation in a report on Wednesday, October 4th. ValuEngine lowered Adamis Pharmaceuticals Corporation from a “hold” rating to a “sell” rating in a report on Tuesday, October 3rd. Finally, Maxim Group reissued a “buy” rating and issued a $13.00 target price on shares of Adamis Pharmaceuticals Corporation in a report on Monday, August 21st.
ILLEGAL ACTIVITY NOTICE: “Adamis Pharmaceuticals Corporation (ADMP) Receives Daily Media Sentiment Rating of 0.14” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/11/20/adamis-pharmaceuticals-corporation-admp-receives-daily-media-sentiment-rating-of-0-14.html.
Adamis Pharmaceuticals Corporation Company Profile
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).
Receive News & Stock Ratings for Adamis Pharmaceuticals Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals Corporation and related stocks with our FREE daily email newsletter.